Joseph J. Ferra Jr. - 06 Jan 2023 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
INTERIM CEO & CFO
Signature
/s/ Robert Yang, Attorney-in-Fact
Issuer symbol
ELEV
Transactions as of
06 Jan 2023
Net transactions value
$0
Form type
4
Filing time
10 Jan 2023, 15:24:27 UTC
Previous filing
19 Dec 2022
Next filing
17 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Stock Option (Right to Buy) Award $0 +240,000 $0.000000 240,000 06 Jan 2023 Common Stock 240,000 $0.7500 Direct F1
transaction ELEV Stock Option (Right to Buy) Award $0 +30,000 $0.000000 30,000 06 Jan 2023 Common Stock 30,000 $0.7500 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vested as to 25% of the total shares on January 6, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 The stock option vests as to 1/6 of the total shares monthly, commencing on February 6, 2023, until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.